Plasmalemma vesicle associated protein (Plvap) is an endothelial protein with roles in endothelial diaphragm formation and maintenance of basal vascular permeability. At the same time Plvap has roles in immunity by facilitating leukocyte diapedesis at inflammatory sites and controlling peripheral lymph node morphogenesis and the entry of soluble antigens into lymph node conduits. Based on its postulated role in diapedesis, we have investigated the role of Plvap in hematopoiesis and show that deletion of Plvap results in a dramatic decrease of IgM + IgD lo B cells in both the spleen and peritoneal cavity. Tissue specific deletion of Plvap demonstrates that the defect is B cell extrinsic, as B cell and pan hematopoietic Plvap deletion has no effect on IgM + IgD lo B cell numbers. Endothelial specific deletion of Plvap in the embryo or at adult stage recapitulates the full Plvap knockout phenotype whereas endothelial specific reconstitution of Plvap under the Chd5 promoter rescues the IgM + IgD lo B cell phenotype. Taken together, these results show that # Corresponding Authors:
Introduction
The innate immune response is the host's first and most rapid response to infection with a pathogen, whereas the adaptive immune response involves a complex process including activation, expansion and differentiation of pathogen-specific B and T cells. The development of adaptive immunity requires several days to weeks to generate a longstanding effector and memory immune response (1, 2) . A key transition from innate to adaptive immunity is mediated by the marginal zone (MZ) B and B-1 cells as they produce the first set of low-affinity antibodies against the pathogen (3) . MZ B and B-1 cells are localized in marginal sinus and peritoneal cavity, respectively, where they are favored as the first cells to sample antigens in the blood and gut. Moreover, MZ and B-1 B cells are well characterized as having a low activation threshold and their BCRs recognize a wide range of microbial antigens (4) . Both B cell subsets significantly contribute to levels of serum IgM, and the production of natural antibodies. Natural antibodies in many cases can be specific to pathogen-encoded molecules and be critical in the rapid neutralization of both viruses and bacteria (5) .
MZ B cells arise from bone marrow precursors through transitional B cells, which colonize the periarteriolar lymphoid sheath (5) . The differentiation of transitional B cells to MZ B cells is driven by a weak BCR activity through a dependent pathway Bruton's tyrosine kinase (6) (7) (8) . This and the interaction of NOTCH expressed on transitional B cells with the ligand, Delta-like 1, on endothelial cells induce the differentiation to MZ B cells (9) . The homing of MZ B cells is dependent on circulating sphingosine-1-phosphate (S1P) binding to S1P 1 and S1P 3 receptors expressed in the endothelial cells of blood vessels of MZ (10, 11) . After migration, MZ B cells are retained by the interaction of αLβ2 and α4β1 with ICAM1 and VCAM1, respectively (12) .
In contrast, B-1 cells are competently produced before birth and throughout the first couple weeks after birth. The precursors for B-1 cells have been discovered in the splanchnopleura region, yolk sac and intra-embryonic hemogenic endothelium, fetal liver but they are absent from adult bone marrow (13) (14) (15) (16) . B-1 cells constantly circulate to and from the peritoneal space across the omentum in a process that involves CXCL13, which is likely produced by macrophages (17) . Collectively, these findings show that B cell progenitors migration is highly regulated by molecules expressed on endothelial cells. However, it is not known whether molecules expressed on endothelial cells are involved in B cell differentiation and trafficking.
cells of blood vessel capillaries and venules in select vascular beds and in the heart endocardium and absent from lymphatic endothelial cells. This pattern of expression was fully supported by a large body of literature obtained with two endothelial specific monoclonal antibodies that bind Plvap, such as MECA-32 (30, 31) in the mouse and PAL-E (32) (33) (34) in humans (reviewed in (35, 36) ). However, recently Plvap expression was also demonstrated in the sinus lymphatic endothelial cells of peripheral lymph nodes (PLN) while confirming its absence from peripheral lymphatics elsewhere ((27) and immgen.org). At the whole organism level, endothelial diaphragms formed by Plvap (24, 37, 38) are critical for maintaining basal permeability of fenestrated blood vessels, their absence resulting in disrupted blood homeostasis and reduced survival (26, 28) . In PLN, Plvap positive diaphragms in the sinus lymphatic endothelial cells control the entry of soluble antigens and lymphocytes in PLN parenchyma (27) .
The expression of Plvap and diaphragm formation is increased in activated endothelial states associated with inflammation (39, 40) and physiological and pathological angiogenesis (35, 41, 42) where it has active roles. Plvap is required for cancer progression (43) and diapedesis of leukocytes into inflammation sites in vivo (31) . In vitro Plvap knock-down and antibody-mediated blockade experiments, suggest that endothelial Plvap is important for the transcellular transmigration but not for adhesion and rolling of lymphoblasts with no effect on neutrophils transmigration (31) . Plvap is thought to control the transcellular migration of lymph-borne lymphocytes into PLN parenchyma (27) . Deletion of Plvap results in defective PLN morphogenesis with mild decreases in the T cell compartment (both CD4 and CD8 T cells), hyperplastic B cell follicles and increases in both PLN B and T cells activation. Intriguingly, Plvap deletion increases the entry of adoptively transferred lymph borne splenocytes (both B and T cells) whereas its ligation with MECA-32 antibody inhibits the recruitment of these subsets (27) . The mechanism of how Plvap mediates transendothelial migration of immune cells in currently unclear.
Here, we have examined whether Plvap plays a role in the development and homeostasis of hematopoietic lineages taking advantage of recently created genetic models of Plvap gain and loss of function and endothelial specific reconstitution (26) . Our studies show that deletion of Plvap results in an intense reduction of IgM + B cells in both spleen and peritoneal cavity. Tissue specific deletion of Plvap demonstrates that the defect is B cell extrinsic, as B cell and pan hematopoietic Plvap deletion has no effect on IgM + B cell numbers. Endothelial specific deletion of Plvap recapitulates full Plvap knockout, while endothelial specific reconstitution of Plvap rescues the IgM + B cell phenotype. Taken together these results demonstrate that Plvap expression on endothelial cells is key in the maintenance of IgM + B cells into spleen and peritoneal cavity. mice where Plvap was deleted in: a) germline (label Plvap −/− , genotype Plvap −/− ;CMVcre tg/+ ) using CMV-cre tg/+ transgenic mice, (JAX strain BALB/c-Tg (CMV-cre)1Cgn/J ). b) endothelial and hematopoietic cells in the embryo using Ins-VEC-cre transgenic mice (44) (label Plvap ECKO-VEC , genotype Plvap L/L ;Ins-VEC-cre tg/+ ) c) endothelial and hematopoietic cells in the embryo using Tie2/Tek-cre tg/+ mice (JAX strain B6.Cg-Tg(Tek-cre)12Flv/J) (label Plvap ECKO-Tie2 , genotype Plvap L/L ;Tek-cre tg/+ ) d) B cell specific deletion of Plvap in the embryo using CD19-cre KI/+ knock-in mice, (JAX strain B6.Cg-Cd19 tm1(cre)Cgn /J) (45) (label CD19 Cre xPlvap L/L , genotype Plvap L/L ;CD19-cre ki/+ ) e) hematopoietic cells in the embryo using Vav1-cre+/− transgenic mice (46) , for deletion of Plvap in all the hematopoietic cell lineages but not in endothelium (44, 46) ; f) for inducible deletion of Plvap in the endothelial cells of the adult mice we used end-SCL-Cre-ERT tg/+ transgenic mice to generate mice with the genotype: Plvap L/L ; end-SCL-CreER T tg/+ (label Plvap iECKO ). Deletion of Plvap was achieved by dosing 4 weeks old mice (both males and females) by gavage with 7 doses of 4mg tamoxifen spaced at 48 hours. Experiments were carried out two weeks after the last tamoxifen dose administration. Control animals for germline deletion were sex and age matched WT or CMV-cre tg/+ (labeled WT) and Plvap +/− or Plvap +/− ;CMV-cre tg/+ (labeled Plvap +/− ) littermates. Control animals for tissue specific deletions were sex and age matched WT or Plvap L/L littermates.
VEC-Plvap-HA tg/+ transgenic mice (26) that express Plvap-HA fusion protein specifically in the endothelial cells under the control of cadherin 5 (VE Cadherin) promoter, were used to reconstitute Plvap in endothelial cells in the context of the Plvap−/− (label PV1 ECRC ) as described (26) . The same strategy was used to reconstitute Plvap in the context of Plvap iECKO (label Plvap iECRC , genotype Plvap L/L ; end-SCL-CreER T tg/+ ; VEC-Plvap-HA tg/+ ).
All animals were maintained in a pathogen-free facility at Dartmouth College. All procedures were approved by the local IACUC.
Antibodies, Staining and analysis by flow cytometry
The following antibodies and staining reagents were used: IgG1 (clone A85-1), IgG2a/b (clone R2-40), CD138 (clone 281-2), IgM (clone 11-41), CD24 (clone M1/69), CD4 (clone RM4-5), CD21/35 (clone 7E9), CD8 (clone 53-6.7), CD25 (clone 3C7), CD62L (clone MEL-14), CD69 (clone H1.2F3), CD44 (clone lM7), CD11c (clone HL3), CD80 (clone 16-10A1), CD86 (clone GL1), CD11b (clone M1/70), c-Kit (CD117, clone 2B8), streptavidin-PerCP, from BD Pharmingen; Plvap (clone MECA-32) was from Abcam; CD38 (clone 90), B220 (clone 6B2), CD23 (clone B3B4), and IgD (clone 11-26c), FceRI (clone MAR-1) from eBioscience; peanut agglutinin from Vector Laboratories. MECA-32 mAb (anti mouse Plvap rat IgG2a) secreting hybridoma was obtained from the Developmental Studies Hybridoma Bank (DSHB, U. Iowa) was produced in serum free conditions by BioXCell (Lebanon, NH). The antibody was labeled with AlexaFluor (AF) fluorochromes using the protein labeling kits for AF488, and AF647 (Invitrogen), as per manufacturer's instructions. Flow cytometry was performed on either a refurbished FACSCAN or a FACSCalibur running CellQuest software (BD), or a FACSCanto running FACSDiva software within the Norris Cotton Cancer Center DartLab Immune Monitoring Facility. The data analysis performed using FlowJo (Tree Star, Inc.).
Isolation of cells from spleen, peripheral lymph nodes and Peyer's patches
To analyze B, T cells and monocytes, single-cell suspensions of lymphocytes were prepared from spleens by mechanical disruption in HBSS followed by passing the cells through a 70μm cell strainer. In experiments where dendritic cells were profiled an enzymatic digestion step (45min, 37°C) was included using DNAse (10 mg/mL Roche) and Liberase (12.5 mg/mL, Roche) before mechanical disruption. Cells were collected by centrifugation (5min, 500xg, 4°C) and red blood cells were lysed (2min, 37°C) using RBC Lysis buffer (BioLegend). Total number of cells and cell viability were determined using either a hemacytometer and trypan blue or a Guava system (Millipore). Cells (10 5 -10 6 ) were stained with antibody cocktails, as noted. Analysis was performed after co-staining with the cocktail of antibodies by flow-cytometry. For isolation of peritoneal cells, the peritoneal cavity was flushed with 5 mL warm (37°C) PBS, 2% BSA, 2mM EDTA, 0.02% sodium azide and 10 U/mL Heparin.
Analysis of Plvap expression in splenocytes of naïve and LPS treated mice
Female wild type C57Bl6/J mice were either treated with 50 μg of LPS (E. coli 055:B5, Sigma) in PBS or an equal volume of PBS alone (control mice), i.p. 12 hrs before spleens were harvested, enzymatically dissociated, as noted above, followed by antibody staining of splenocytes, and analyzed by flow cytometry.
Immunofluorescence and Laser Confocal microscopy
Tissues were snap-frozen in optimal cutting temperature medium and sectioned to 8 μm. Sections were collected on charged slides (Surgipath) fixed (−20°C, 10min) with cold methanol, rinsed (3×2min, RT) in PBS, encircled with hydrophobic barriers (PapPen), blocked (30min, RT) with 10% rat serum in PBS containing 10μg/ml mouse Fc block, incubated (1h, RT, in dark) with various fluorescently labeled primary antibody cocktails in blocking buffer, rinsed (3×5min, RT, in dark) again in PBS, stained (10min, RT, in dark) with 300 nM 40,6-diamidino-2-phenylindole dihydrochloride (DAPI, D1306; Life Technologies) and washed (3× 5 min, RT) in PBS. Labeled sections were mounted under #1.5 coverslips using a polymerizing mounting medium (Fluoromount G, Southern Biotech). The antibodies used were: rat anti-mouse Plvap-AF568 (clone MECA-32), rat anti-mouse CD169 -FITC (clone MOMA-1, AbD Serotec) and rat anti-mouse/human B220-AF647 (clone 6B2). Labeled sections were analyzed using a Zeiss LSM510 Meta confocal microscope equipped with appropriate lasers (405 nm, 488 nm, 532nm, 633nm) and filters, all within the Norris Cotton Cancer Center microscopy facility. The acquired images were processed for brightness and contrast and analyzed using ImageJ (http://imagej.nih.gov/ij/), and the figures were mounted using Adobe Photoshop and Adobe Illustrator CS6.
Statistics
Results are expressed as mean plus or minus SEM. Two-tailed Student t test with unequal variance was used to evaluate the statistical significance of the data. 
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Results

Deletion of Plvap in mice results in reduced numbers of splenic IgM + B cells
Plvap is an endothelial protein that is involved in the diapedesis of leukocytes at sites of inflammatory challenge and PLN sinuses. Diapedesis is a process that is central to the development and homeostasis of hematopoietic lineages. To understand the role of Plvap in these processes, we used recently generated Plvap −/− mice (26) to characterize the function of this molecule on the numbers and subset composition of leukocytes in the blood, spleen, PLN and Peyer's patches (PP). Plvap −/− , Plvap +/− and wild type (WT) littermate control mice were profiled by flow cytometry to determine whether there are modifications in terms of leukocyte subset numbers, frequency or function. No differences were found in cellular composition of peripheral blood, LN and PP with respect with percentages, number and viability of granulocytes, T-and B-lymphocytes, NK cells and monocytes ( Fig. 1A , supplemental Fig. S1 and data no shown). In the spleen, there was a drastic reduction in the percentage and absolute number of IgM + IgD − B cells in Plvap −/− mice ( Fig. 1B and 1C ), whereas IgD + B cells were not affected ( Fig. 1B ).
In the spleen, there are several prominent B cell subsets that are represented (47) . To evaluate whether the reduction of this population is due to a reduction of a specific subpopulation of splenic B cells, we stained with a panel of antibodies that identify those subpopulations (47) . Due to the drastic reduction of cells in the peritoneum cavity of Plvap −/− mice, we also analyzed the percentage of mast cells and monocytes in this compartment. Our results show that mast cells (cKit + FceRI + cells, supplemental Fig. S2A ) and monocyte (CD11b + Gr-1 + cells, data not shown) percentages were also reduced in Plvap −/− mice compare with control mice, indicating that Plvap is an important molecule in migration to, or retention into the peritoneum.
Plvap deletion within the hematopoietic compartment does not impact on the frequency of B cells in the spleen and peritoneum
To understand the underlying mechanisms responsible for altered B cell frequencies in the spleen and peritoneum, we sought to determine whether these effects are B cell intrinsic or extrinsic. First, we inquired whether Plvap was expressed on hematopoietic cells and, second, established the impact on B cell frequencies of genetic B-cell specific and panhematopoietic deletion of Plvap.
LPS-activated or resting B cells or dendritic cells did not express Plvap, as detected with antibody staining and using Plvap −/− splenocytes as controls. Furthermore, CD4 + and CD8 + T cells were also negative for Plvap expression (Fig. 3A, B and C). Examination of Plvap expression by confocal microscopy revealed that expression was limited to the splenic blood vessels in the MZ area (determined by MOMA-1+ macrophage localization) ( Figure 3D ). Taken together, these data suggest that Plvap is not expressed within the hematopoietic subsets studied, in agreement with recent data published by the Immunological Genetic Consortium (immgen.org) (49) .
While expression analysis conclusively established the lack of hematopoietic expression of Plvap, genetic deletion of Plvap in hematopoietic cells and subsets was used to confirm these findings. Plvap L/L mice were interbred with CD19-Cre (45) or Vav1-Cre mice (46) to obtain compound mice lacking Plvap in the B cells (CD19 Cre xPlvap L/L ) or all hematopoietic cells (Vav Cre xPlvap L/L ) (26), respectively. Vav Cre xPlvap L/L mice have over 97% Plvap deletion in the hematopoietic compartment (26) . B cells isolated from CD19 Cre xPlvap L/L mice using magnetic separation showed >95% deletion of Plvap (data not shown). Immune profiling of the peritoneal lavage showed that there was no effect on B frequencies or phenotype in the spleen and peritoneum in either CD19 Cre xPlvap L/L (Fig. 4A -B) or Vav1 Cre xPlvap L/L ( Fig. 4C-D) mice. The combination of microscopy, flow cytometry, and genetic data clearly demonstrate that Plvap is not expressed in the hematopoietic compartment and that the maintenance of IgM + B cells in both spleen and peritoneal cavity is due to Plvap expression outside the hematopoietic compartment.
Plvap deletion on endothelial cells reduces IgM + B cells in spleen and peritoneum
Plvap is a molecule specifically expressed in endothelial cells of blood vessels (26, 29) and PLN sinus (27) , suggesting that endothelial cells might impact on the presence of IgM + B cells in spleen and peritoneum. For this purpose, we made use of Tie2 Cre xPlvap L/L mice (26) where Plvap is efficiently (>95%) deleted in the endothelial cells and the hematopoietic compartment at embryonic stage. The results obtained in Tie2 Cre xPlvap L/L mice phenocopied those obtained in Plvap −/− mice. There was a reduction in IgM + IgD − B cell percentage in the spleen from Tie2 Cre xPlvap L/L compared with control littermates (Fig. 5A-C) . Additionally, there also was a striking reduction in the percentage of IgD + and IgM pos IgD − B cells in the peritoneal cavity of Tie2 Cre xPlvap L/L compared to control mice ( Figure  5D -F). These data suggest that the expression of Plvap on endothelial cells regulates the numbers of IgM + B cells in the spleen and peritoneal cavity.
Endothelial reconstitution of Plvap rescues the Plvap−/− phenotype and restores B cell frequencies in the spleen and peritoneal cavity
In order to demonstrate that Plvap −/− phenotype is not due to a distortion of other genetic loci close to the Plvap locus, we transgenically complemented the Plvap-deficiency by the expression of Plvap-HA in endothelial cells of Plvap −/− mice (26) . Previously, we have generated mouse lines (VEC-Plvap-HA +/tg ) ta (26) expressing Plvap under the control of the VE Cadherin promoter and 5′ intronic enhancer (50) . We used VEC-PlvapHA +/tg and Plvap +/− mice, to generate compound Plvap −/− ; VEC-PlvapHA +/tg (Plvap ECRC ) mice, which display between 30% and 50% reconstitution of native endothelial Plvap levels (26) .
As shown in Fig 
Plvap deletion in blood vessel endothelial cells does not affect the development of B cells in the bone marrow
To determine whether Plvap deletion leads to a defect in B cell development in bone marrow, we profiled B cells progenitors in the marrow of Plvap L/L ; end-SCL-CreER T tg/+ compound mice (Plvap iECKO ) and mice with endothelial reconstitution of Plvap in the context of the Plvap iECKO (labeled Plvap iECRC mice) (see Methods). The promoter driving the expression of CreER T fusion protein consists of SV40 virus minimal promoter and the endothelial enhancer of the Stem Cell Leukemia gene (SCL) (51) . This compound promoter confers activity in endothelial cells from select vascular beds, bone marrow included, as previously shown (51, 52) . To minimize the effects on the peritoneal cavity the tamoxifen was administered by gavage.
As shown in Fig. 7A and 7B , IgM + IgD low B cells are reduced in both spleen (Fig. 7A-B ) and peritoneum ( Fig. 7C-D) of Plvap iECKO mice compared to control (tamoxifen treated Plvap L/L ) mice, whereas endothelial reconstitution in Plvap iECRC mice reverses the effect. In addition, IgD + B cells were also reduced in the peritoneum of Plvap iECKO mice (Fig. 7C-D) , indicating that endothelial deletion in adult mice has a similar phenotype as that obtained in Plvap −/− mice with respect to B-1 and MZ B cells. (Fig. 1 ).
Using these models, we analyzed the proportion of immature B cells (B220 + IgM hi IgD + ), mature B cells (B220 + IgM int IgD + ) and pre-B cells (B220 + IgM + IgD + ) from bone marrow (53, 54) . However, no changes were detected in B cell subsets in the bone marrow of Plvap iECKO mice as compared to controls or Plvap iECRC mice (Fig. 7E-G) . These results together suggest that the defect observed in the splenic immature B cells and peritoneum B cells are not due to a defect in the B cell development in the bone marrow.
Discussion
The (31), we could not find Plvap expression by antibody staining in a variety of circulating or parenchymal murine immune subsets. Our data is in accordance with RNAseq data on Plvap expression, published by immgen.org (49, 56) . Additionally, we found that neither B cells nor dendritic cells express Plvap in basal or under inflammatory (LPS stimulation) conditions. Furthermore, when we abrogate Plvap expression on B cells or in the hematopoietic compartment, there is no effect on the abundance of IgM + B cells in the spleen or peritoneum. These findings suggest that if Plvap has a B cell trafficking/retention function in the spleen or peritoneum, this role is not B cell or hematopoietic cell intrinsic. In contrast, when we used a mouse model where the lack of Plvap was specific to endothelial cells, the defect in B cell migration/retention was indistinguishable from that observed in the global Plvap deficient mice. Furthermore, the transgenic overexpression of Plvap expression on endothelial cells in Plvap deficient mice rescued the phenotype. Together, these results demonstrate that Plvap expression in endothelial cells is key in the B cell trafficking/ retention in the spleen and peritoneum.
a.
Plvap might hamper the generation of the B-1 B cell hematopoietic progenitors in the vascular plexus of the amniotic sac and hemogenic endothelium (16, 57, 58) where Plvap is expressed very early (18, 59) . Preliminary data show that the number of B-1 B cell progenitors in the amniotic sac (Yoshimoto, Yoder, Stan unpublished) at E9 in the WT, Plvap L/L and Plvap−/− is similar. In addition, B cells precursors in the bone marrow are also similar in the Plvap deficient mice (Figure 7) , which makes Plvap involvement in B cell development unlikely.
b.
Plvap controls B-1 and MZ B cell recruitment and/or retention in the peritoneum and spleen, respectively. Integrins, chemokines and other adhesion molecules have been shown to be involved in B cell migration (12, (60) (61) (62) . Different types of adhesion molecules regulate distinct events in lymphocyte extravasation. We know from these studies that integrins play a role in leukocyte tethering, whereas chemokines play a role in the rolling process (63) . Immature B cells express αLβ2 and α4β1, which retain B cells in the splenic marginal sinus, where they interact with their ligand, ICAM1 and VCAM1 expressed in endothelial cells (12) . In addition, an increased gradient of CXCL13 in the periarterial lymphocyte sheath induces the migration of B cells from marginal zone to the follicles (64) . In contrast, S1P 1 expressed on B cells is able to induce the migration of B cells to the sinus of marginal zone and peritoneum (10, 11, 65) .
Conceivably S1P 1 expressed on B cells could interact with Plvap, through vim, to permit the extravasation of B cell progenitors to peritoneum and the splenic marginal sinus. However, additional studies are necessary to test this hypothesis.
Plvap may also be an integral mediator of inflammation-induced migration. It has been previously observed that the blocking of Plvap in vivo reduced the number of monocytes found in the peritoneum after the induction of peritonitis (31) . Our results show that Plvap has a novel role in the progression of leukocyte migration to peritoneum not just in inflammation but also in the steady state. The global deletion or specific obliteration of Plvap in endothelial cells reduced the migration not just of B cells but also others leukocytes by approximately 80% in steady state. In addition, when we restore the expression of Plvap exclusively in endothelial cells, we observed the rescue of B cells number in steady state, suggesting that Plvap expression in endothelial cells is the master regulator of immune cell migration to peritoneum. In conclusion, the expression of the glycoprotein Plvap on endothelial cells is a key regulator of B cells in the peritoneum, as well as, immature IgM + B cells in the spleen. It also has a physiological role in facilitating the production of natural IgM and IgA antibodies by peritoneal and splenic IgM + B cells. Collectively, our findings point to a novel immunologic significance for Plvap in innate humoral immunity. Future work will determine the precise mechanism by which Plvap regulates B cell subsets in peritoneum and spleen. 
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